"Our inclusion in the Global 100 list is a testimony to our longstanding commitment to corporate responsibility," said Joseph Jimenez, CEO of Novartis. "Being recognized among the top 100 sustainability performers in the world underscores that doing business responsibly is a core part of Novartis."
Inclusion in the index is determined using 12 quantitative social, environmental and governance indicators, such as innovation capacity, employee turnover and leadership diversity.
Novartis aims to improve global health. Through our business, we make an important contribution to society: We discover and develop innovative medicines and vaccines. We collaborate with others to help address some of the world's greatest health challenges. To earn the trust of these collaborators and our customers, we need to do business responsibly, in a way that underscores our mission of caring and curing. We work to control and eliminate diseases, pioneer new business approaches to reach under-served patients, and find new treatments to improve health in developing countries. We also care for our associates, strive to positively contribute to our communities, and protect the environment. We conduct business ethically, maintaining a Code of Conduct and governance system to ensure associates uphold our values.
Recent recognition for our corporate responsibility activities includes being listed in the STOXX Global ESG Leaders Index for the third consecutive year; being recognized among the 25 best multinational employers by Great Place to Work® Institute; and being ranked top pharmaceutical company in Fortune's World's Most Admired Companies for the third year in a row.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 133,000 full-time equivalent associates and operate in more than 140 countries around the world.